
Paul Wilson
Editor at Implementation Science
Work in Manchester, live in Leeds. Evidence informed decision making. Co Editor @ImplementSci Views my own.
Articles
-
3 weeks ago |
thehindu.com | Paul Wilson
With an enrollment of more than 41 million students, India has been recognized as the world’s second largest post-secondary education system (after China). In the New Education Policy 2020 (NEP), the Government of India projects to increase the enrollment rate to 50%, from its current 27.3%, by 2035. To achieve this goal, India will have to add around 34 million students to the system. South India has been facing a decline in enrollment in Mathematics and Basic Sciences progressively.
-
2 months ago |
walshmedicalmedia.com | Paul Wilson
Short Communication - (2025) Volume 10, Issue 2 Meningitis: Understanding the Disease, Causes and Prevention Strategies Paul Wilson* Department of Biosciences, Durham University, Durham, United Kingdom *Correspondence: Paul Wilson, Department of Biosciences, Durham University, Durham, United Kingdom, Email: Received: 25-Feb-2025, Manuscript No. JIDD-25-28665; Editor assigned: 27-Feb-2025, Pre QC No. JIDD-25-28665 (PQ); Reviewed: 14-Mar-2025, QC No. JIDD-25-28665; Revised: 21-Mar-2025,...
-
Mar 13, 2025 |
msn.com | Paul Wilson
Microsoft Cares About Your PrivacyMicrosoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will personalise the content and ads that you see. You can select ‘I Accept’ to consent to these uses or click on ‘Manage preferences’ to review your options and exercise your right to object to Legitimate Interest where used.
-
Feb 1, 2025 |
bmjopen.bmj.com | Paul Wilson |Rebecca Elvey |Amy Mathieson |Peter Bower
AbstractObjectives VICTORION-Spirit was a hybrid study designed to assess the feasibility of implementing inclisiran, a novel cholesterol-lowering treatment and behavioural support within primary care centres in England. This process evaluation aimed to evaluate the implementation of inclisiran for patients with elevated low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (n=900), from the perspectives of key stakeholders.
-
Jan 22, 2025 |
msn.com | Paul Wilson
Microsoft Cares About Your PrivacyMicrosoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will personalise the content and ads that you see. You can select ‘I Accept’ to consent to these uses or click on ‘Manage preferences’ to review your options and exercise your right to object to Legitimate Interest where used.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 645
- Tweets
- 2K
- DMs Open
- Yes